In the first stage, the primary objective of Borean Pharma is to establish
an organization, able to bring the technology platform forward to such a
rank level of maturation that opens the possibility for initiating the
development of an array of concrete product candidates in alliances with
established pharma companies. The accomplishment of this assignment is
already well under way, and Borean Pharma is expected to be ready to proceed
to the next stage in 2003. As a technology-based company it is of immense
importance for Borean Pharma to maintain a proactive IPR strategy, as this a
key factor in the securing of value adding, and this aspect has therefore
been high in the list of priorities already from commencement as a frame
around Borean Pharma’s research- and developing activities.
The Company has during 2002 expanded the total staff from 5 to 21, and by
the recruitment of additional 10-15 new colleagues, this staff number is
expected to be sufficient to establish a first partner collaboration.
The construction of the central part of Borean Pharma's technology platform
was made possible by building on combinatorial protein engineering tools
developed elsewhere for the creation of one of the technologies that enabled
the generation of ‘fully human’ therapeutic monoclonal antibody products.
Borean Pharma has extended the application of the combinatorial protein
technology to a new class of human proteins of the so-called ‘C-type lectin
related protein’ family, and demonstrated that these slightly modified
‘designer proteins’ can be used as antibody mimics, which are expected to
lay the foundation for a new generation of safe competitive protein
therapeutics. C-type lectins have a distinct ”LEGO”-structure and are easy
to re-configure. In contrast, antibody molecules have a complicated
architecture and are costly to produce on an industrial scale. Borean Pharma
has established a dominant patent position for all aspects of the technology
and holds a number of patents and patent applications.